The short version
- Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- What the evidence isA published phase 2 safety and efficacy trial of SkQ1 ophthalmic solution in dry eye, run both in the ordinary environment and under a Controlled Adverse Environment challenge (Petrov 2016) — the methodology the US regulatory pathway for dry eye actually uses.
- What to watchEye pain, redness or swelling.
How Visomitin works
The delivery system is the invention, and it runs on physics rather than on biology. SkQ1 is a plastoquinone head group joined by a ten-carbon linker to a triphenylphosphonium cation.
What the head group does once it is there. Plastoquinone is the electron carrier plants use in photosynthesis, and in this context it acts as a chain-breaking antioxidant inside the lipid phase of the membrane it has concentrated into. Lipid peroxidation propagates through membranes as a radical chain; an antioxidant dissolved in water cannot reach it, which is the design problem the cation solves.
The cation is the delivery mechanism and it is the whole idea: a lipophilic positive charge is driven across membranes by the electrical potential they carry, and the mitochondrial inner membrane carries the largest potential in the cell, so the molecule accumulates there by electrophoresis rather than by any receptor. The plastoquinone then does what it does in a chloroplast — intercepts the lipid peroxidation chain in the membrane it is sitting in. Concentration is the whole safety argument, because the same charge that concentrates it will uncouple respiration if there is too much of it.
- Topical
On the goal map: Glycation, oxidation & protein damage (Longevity & healthspan)
Research on Visomitin8 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Registered in Russia as an eye drop — the only registered SkQ1 medicine anywhere. One published phase 2 trial in dry eye. Not FDA-approved.
Human clinical evidence
A published phase 2 safety and efficacy trial of SkQ1 ophthalmic solution in dry eye, run both in the ordinary environment and under a Controlled Adverse Environment challenge (Petrov 2016) — the methodology the US regulatory pathway for dry eye actually uses.
No SkQ1 product holds a United States approval (Valdes-Arias 2024). The Russian registration is real and it is a different standard.
Correlative data
SkQ1 protected cornea against oxidative damage from ultraviolet irradiation and mechanical injury in animals (Zernii 2018) — local delivery to the surface it was applied to.
A clean negative, published with Skulachev on the author list: SkQ1 and MitoTEMPO failed to exert a long-term beneficial effect in murine polymicrobial sepsis (Rademann 2017).
The most recent extension away from the eye is osteoclast metabolism and bone loss through a STAT3/LDHB axis (Yuan 2025) — mechanistic animal and cell work, not a human result.
How the mechanism reads
The delivery mechanism is physics rather than biology: a lipophilic cation is driven into mitochondria by the membrane potential, roughly 150-180 mV negative inside, which predicts several hundred-fold accumulation with no receptor involved.
MechanisticThe same charge is the toxicity. Above its useful range the molecule uncouples the mitochondria it concentrates into, which is why the registered ophthalmic strength is 0.155 mcg/mL (0.0000155%).
MechanisticThe serum and hydrogel sold at the same price have no controlled human trial of any kind. What the phase 2 established, it established for an eye drop in an eye.
Mechanistic
Sources
- Petrov A, Perekhvatova N, Skulachev M, Stein L, Ousler G. SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model. Advances in Therapy 2016 · PMID 26733410
- Rademann P, Weidinger A, Drechsler S, Meszaros A, Zipperle J, Jafarmadar M, Dumitrescu S, Hacobian A, Ungelenk L, Rostel F, Kaszaki J, Szabo A, Skulachev VP, Bauer M, Bahrami S, Weis S, Kozlov AV, Osuchowski MF. Mitochondria-Targeted Antioxidants SkQ1 and MitoTEMPO Failed to Exert a Long-Term Beneficial Effect in Murine Polymicrobial Sepsis. Oxidative Medicine and Cellular Longevity 2017 · PMID 29104729
- Zernii EY, Gancharova OS, Tiulina VV, Zamyatnin AA Jr, Philippov PP, Baksheeva VE, Senin II. Mitochondria-targeted antioxidant SKQ1 protects cornea from oxidative damage induced by ultraviolet irradiation and mechanical injury. BMC Ophthalmology 2018 · PMID 30587174
- Suarez-Rivero JM, Pastor-Maldonado CJ, Povea-Cabello S, Alvarez-Cordoba M, Villalon-Garcia I, Munuera-Cabeza M, Suarez-Carrillo A, Talaveron-Rey M, Sanchez-Alcazar JA. Coenzyme Q10 Analogues: Benefits and Challenges for Therapeutics. Antioxidants (Basel) 2021 · PMID 33557229
- Yuan P, Feng Z, Yang H, Xue H, Xie H, Dai Z, Wang H, Liu Y, Pan B, Song H, Ye H, Xie Z, Shi P, Sun X. Visomitin Attenuates Pathological Bone Loss by Reprogramming Osteoclast Metabolism via the STAT3/LDHB Axis. Research (Washington DC) 2025 · PMID 40698330
- Ji MH, Kreymerman A, Belle K, Ghiam BK, Muscat SP, Mahajan VB, Enns GM, Mercola M, Wood EH. The Present and Future of Mitochondrial-Based Therapeutics for Eye Disease. Translational Vision Science and Technology 2021 · PMID 34232272
- Valdes-Arias D, Locatelli EVT, Sepulveda-Beltran PA, Mangwani-Mordani S, Navia JC, Galor A. Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease. Drugs 2024 · PMID 38652355
Visomitin safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Eye infection, injury or a contact lens that is irritating: use the drop only on a healthy eye.
- Pregnancy or breastfeeding: only the registered Russian eye drop has any human data.
- Wanting an oral or injected version: those forms are not the registered medicine.
- Allergy to triphenylphosphonium compounds.
What’s expected
- Brief stinging after the drop.
- Less dry-eye discomfort, per one phase 2 trial.
- Antioxidant action concentrated inside mitochondria; at high exposure it can act the other way.
Watch for
- Eye pain, redness or swelling.
- Blurred vision that does not clear.
- Light sensitivity.
- Hives while using Visomitin.
Labs that tell you it’s working
- F2-Isoprostane/Creatinine (Urine)
- Coenzyme Q10
- hs-CRP (C-Reactive Protein, High Sensitivity)
SkQ1 ties plastoquinone to a triphenylphosphonium cation that accumulates in mitochondria; oxidative stress markers test the antioxidant claim. PMID 26733410
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Visomitin FAQ4 common questions
- Is Visomitin approved for human use?
- Visomitin is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is Visomitin researched for?
- Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- Which labs show whether it's doing anything?
- F2-Isoprostane/Creatinine; Coenzyme Q10; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Visomitin: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



